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A MYRIAD OF REASONS: INCENTIVES FOR INNOVATION
IN GENETIC RESEARCH AND DIAGNOSTICS POSTMYRIAD
ZACHARY KLING*
INTRODUCTION
Imagine a world in which the very essence of your being is owned
by various corporations and institutions. These groups profit off of
ascertaining exactly what is contained within your genetic code. They
exclude you and others from learning what your code says about you,
unless you pay them for the information. In a manner, this is what
has been happening in the field of genetic diagnostics for many years
XQWLO WKH 6XSUHPH &RXUW¶V GHFLVLRQ LQ Association for Molecular
Pathology v. Myriad.1
On January 3, 2000, British artist Donna Rawlinson Maclean
attempted to reserve her unique genetic code by submitting a patent
application titled ³0\VHOI´2 She filed her application, GB0000180.0,
in the British Patent Office to protest the above-described scenario.3
Brian Caswell, an agent at the British Patent Office, seemed confused
as to why someone would submit such a patent.4 On the topic of the
SDWHQW DSSOLFDWLRQ &DVZHOO VDLG ³,W LV QRW UHDOO\ ZRUWK SDWHQWLQJ
VRPHWKLQJXQOHVV\RXPDNHDORWRIPRQH\IURPLW´5

* J.D. Candidate at Indiana University Robert H. McKinney School of Law.
1.See $VV¶QIRU0ROHFXODU3DWKRORJ\Y0\ULDG*HQHWLFV,QF6&W
(2013).
2. Of Her Own Making, N. Y. TIMES, (Mar. 12, 2000),
http://www.nytimes.com/2000/03/12/business/business-diary-of-her-ownmaking.html, archived at http://perma.cc/CQ6K-MXSV.
3. Id.
4.Woman Files Patent Application on Herself, INST. FOR AGRIC. AND TRADE
32/¶< 0DU KWWSLDWSRUJnews/biotech-activists-030300-woman-filespatent-application-on-herself, archived at http://perma.cc/M5K9-XKSJ.
5. Id.

1
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Undoubtedly, Ms. Maclean was not likely to realize robust profits
from her patent, or any at all, but a lot of money had been made from
products protected from competition by genetic patents at that time.
For instance, in the year 2000, one product protected by a gene patent
DFFRXQWHGIRUPRUHWKDQELOOLRQRIRQHFRPSDQ\¶VELOOLRQLQ
total revenue.6
The commercializatLRQ DQG PRQRSROL]DWLRQ RI KXPDQLW\¶V VKDUHG
genetic code disturbed more than just a British performance artist
with a flair for the dramatic. Other parties concerned with the
patenting of human genes included medical professionals, researchers
in genetic epidemiology, and policy-makers to name a few.7
As the years went on, more and more of the human genome
became patented.8 In 2009, the controversy came to a head when the
American Civil Liberties Union (ACLU) filed a lawsuit in the
Southern District of New York naming twenty plaintiffs that included
the United States Patent Office, Myriad Genetics, and ten directors of
the University of Utah Research Foundation as defendants.9
This case went all the way to the Supreme Court.10 In the summer
of 2012, in a decisive, unanimous decision penned by Justice
Thomas, the Court found for the plaintiffs on patents that claimed
genomic DNA.11 In this single decision, the Court invalidated the
patents that laid the foundation for an entire industry.12
The decision was a hard-won victory for those concerned with the
ability of private companies to own the rights to the human genetic
6.See Amy Tsao, Amgen: Will Bigger Be Better? BUSINESS WEEK ONLINE, Jan. 2,
2002,
http://www.businessweek.com/bwdaily/dnflash/jan2002/nf2002012_2995.htm.
(EpoGen, a product protected by a patent on the human erythropoietin gene,
DFFRXQWHGIRUELOOLRQGROODUVRI$PJHQ¶VQHDUO\ELOOLRQGROODUUHYHQXHV 
7.Lori B. Andrews, The Gene Patent Dilemma: Balancing Commercial Incentives
with Health Needs, 2 HOUS. J. HEALTH L. & POL¶Y 65, 66 (2002).
8.Kyle Jensen & Fiona Murray, Intellectual Property Landscape of the Human
Genome, 310 SCIENCE (5746) 239-240 (October 14, 2005).
9.28 U.S.C. $VV¶QIRU0ROHFXODU3DWKRORJ\Y8QLWHG6WDWHV3DWHQWDQG
Trademark Office, 702 F. Supp. 2d 181 (S.D.N.Y. 2010).
10.See generally $VV¶QIRU0ROHFXODU3DWKRORJ\Y0\ULDG*HQHWLFV,QF6&W
2107 (2013).
11.Id. at 2119.
12. Id.
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code, but is it possible that they were shortsighted and focused too
QDUURZO\ RQ WKH VHHPLQJO\ XQMXVW QDWXUH RI ³RZQLQJ´ D SHUVRQ¶V
genetic code? After all, the genes in question in Myriad were being
used to identify whether a person may develop breast cancer, a
laudable goal. Perhaps without the security of genetic patents,
researchers would no longer be encouraged to find such gene-todisease correlations. Perhaps that may be the case, but is there
anything left to incentivize researchers? And, if there is, what exactly
is left to incentivize these innovative genetic diagnostics companies?
This Note addresses the incentives remaining for innovation in the
genetLF GLDJQRVWLFV ILHOG DIWHU WKH 6XSUHPH &RXUW¶V GHFLVLRQ LQ WKH
Myriad case. Part I is an overview of patent law in the United States
GHYHORSV WKH UHDGHU¶V XQGHUVWDQGLQJ RI ZKDW D patent is, what is
generally patentable, and the steps necessary to secure a patent in the
United States. Part II discusses genes, genetic diagnostics, and gene
patents. Part III delves into the controversy surrounding gene
patents, including a discussion of both SURSRQHQW¶V DQG RSSRQHQW¶V
positions on the granting of gene patents.
Part IV contains a discussion of Myriad from the district court
all the way up to the Supreme Court that lays out the legal rationale
behind the invalidation of patents the genetic diagnostics community
believed were invaluable to their field. Finally, Part V analyzes what
remains post-Myriad to incentivize genetic researchers to look for
gene sequence associations to diseases and to develop the diagnostics
to test for these gene sequences. This final Part reveals that not all
was lost due to the invalidation of key patents protecting the industry
and that many means remain by which genetic researchers and
diagnostics providers can maintain incentive and competitive
advantage to continue their work.
I.

PATENT LAW IN THE UNITED STATES

Patent law in the United States has its foundation in the Constitution.13 7KH³,QWHOOHFWXDO3URSHUW\´FODXVH WKH´,3FODXVH´ RU³SDWHQW
DQG FRS\ULJKW FODXVH´ FRQIHUV XSRQ the government of the United
States the authority and obligation to provide protection to those who
13.See U.S. CONST. art. I, § 8, cl. 8.
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advance the sciences or the useful arts.14 The IP clause can be found
at Article 1, Section 8, Clause 8 of the United States Constitution and
provides CongrHVV ZLWK WKH SRZHU ³>W@R SURPRWH WKH SURJUHVV RI
science and useful arts, by securing for limited time to authors and
inventors the exclusive right to their respective writings and
GLVFRYHULHV´15 Inventors who have patents issued to them are
UHIHUUHGWRDV³SDWHQWHHV´16
To this end, Congress has enacted legislation to protect inventors
DQG WKHLU DGYDQFHV WR WKH ³XVHIXO DUWV´ E\ SURYLGLQJ SURWHFWLRQ
through what is known as a patent.17 According to the United States
Patent and Trademark OffLFH WKH³86372´ WKHDJHQF\UHVSRQVLEOH
for the issuance of patents and trademark registrations within the
United States, a patent is:
a property right granted by the Government of the United
6WDWHV RI $PHULFD WR DQ LQYHQWRU µWR H[FOXGH RWKHUV IURP
making, using, offering for sale, or selling the invention
throughout the United States or importing the invention into
WKH 8QLWHG 6WDWHV¶ IRU D OLPLWHG WLPH LQ H[FKDQJH IRU SXEOLF
disclosure of the invention when the patent is granted.18
Thus, patent rights are a negative property right.19 Holding a patent
alone does not allow a patentee to actually practice, make, or even
use their invention.20 The patent, as explained in the above quoted
language, allows only the power to exclude others from making use
of the patented invention.21 A prime example of this is in the
pharmaceutical industry. Almost every pharmaceutical product has,
at least at the beginning of its lifecycle, various patents that claim the
chemical composition of the drug or the formulation of the drug

14. Id.
15. Id.
16.35 U.S.C. § 100(d) (2015).
17.See generally 35 U.S.C. §§ 101-103 (2015).
18.Patents for Inventors, USPTO (Jan. 26, 2015),
http://www.uspto.gov/inventors/patents.jsp, archived at http://perma.cc/7YYPRKYP.
19. Id.
20. Id.
21.Id.; see also 35 U.S.C. § 271 (concerning infringement of patents).
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product made with that chemical composition.22 Yet, to reach the
market and actually be able to sell their inventions, innovator
pharmaceutical companies must jump through the regulatory hoops
RIWKH)RRGDQG'UXJ$GPLQLVWUDWLRQ WKH³)'$´ 23
Patents in the United States are more fully governed by the Patent
Act, which is codified at 35 U.S.C. §§ 1±376. To be granted a patent,
Congress established that the claimed invention must be patentable
subject matter as defined in 35 U.S.C. § 101. Patentable subject
PDWWHU LV GHILQHG DV ³DQ\ QHZ DQG XVHIXO SURFHVV PDFKLQH
manufacture, or composition of matter, or any new and useful
LPSURYHPHQW WKHUHRI´24 This definition has been found to exclude
from the realm of patentable subject matter inventions that claim
laws of nature, products of nature, or abstract ideas.25
Further requirements for patentability include novelty,
non-obviousness, and utility.26 Novelty generally requires that the
claimed invention be one that is new and has not been claimed in a
previous patent application in the United States or any other
country.27
Non-obviousness requires that the invention or
modification to a prior invention not be obvious to a person who has
ordinary skill in the science underlying the invention.28 Utility
requires that an invention have some use.29 Thus, one cannot patent
something that has no use or purpose capable of being exploited.30

22.Katherine N. Addison, The Impact of the Biosimilars Provision of the Heath
Care Reform Bill on Innovation Investments, 10 J. MARSHALL REV. INTELL. PROP.
L. 553, 571 (2011).
23.21 U.S.C. § 355(a); See also Katherine N. Addison, The Impact of the
Biosimilars Provision of the Heath Care Reform Bill on Innovation Investments, 10
J. MARSHALL REV. INTELL. PROP. L. 553, 571 (2011).
24.35 U.S.C. § 101 (2012).
25.Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
26.35 U.S.C. §§ 101-103 (2012).
27.35 U.S.C. § 102 (2012).
28.35 U.S.C. § 103 (2012).
29.See 35 U.S.C. § 101 (2012).
30. Id.
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GENES: WHAT ARE THEY AND HOW CAN YOU PATENT THEM?

A.
What is DNA?
When the ordinary, non-scientist thinks of a gene, he or she most
OLNHO\ XQGHUVWDQGV WKDW JHQHWLF LQIRUPDWLRQ LV FDUULHG LQ D SHUVRQ¶V
DNA, and their individual genes are somehow responsible for
making them who they are. It then follows from that understanding
that a single gene is the section of DNA that provides for some
physical characteristic or trait of an individual.31 At the most basic
level, this is essentially correct. However, a little more depth on the
topic of precisely what a gene is and how they have been claimed in
patents will help lay the groundwork for the discussion at hand.
That simplistic take on what a gene is should generally be a
satisfactory working definition for most people, but how do
professional geneticists and other scientists define a gene? Those
scientists cannot even decide what exactly the definition of a gene
ought to be.32 As scientists learn more about biology, and genetics
specifically, the definition of what a gene is and exactly what it does
are in flux.33
Deoxyribonucleic acid (DNA) is the source code for everything
human bodies are programmed to do.34 This includes the information
that is eventually responsible for eye color, hair color, the growth of
limbs, and the ability of nerves to transmit sensations to the brain.35
DNA is structured in a twisted double helix, like a spiraling ladder.36
31.Black Bag at BB4, OAK RIDGE NATIONAL LABORATORIES, available at
http://www.ornl.gov/sci/techresources/Human_Genome/publicat/, archived at
http://perma.cc/29E8-FGQ6
32.See Andrew W. Torrance, Gene Concepts, Gene Talk, and Gene Patents, 11
MINN. J.L. SCI. & TECH   ³>'@HEDWHVDERXWZKDWDµJHQH¶UHDOO\LV
have raged within the
biology FRPPXQLW\´ 
33.Id. at 160-61.
34.See generally National Institutes of Health, A Brief Guide to Genomics,
NATIONAL
HUMAN GENOME RESEARCH INSTITUTE, http://www.genome.gov/18016863,
archived at http://perma.cc/H2GR-JAD7.
35.OAK RIDGE NATIONAL LABORATORIES, supra note 31, at BB4
36.James D. Watson & Francis H. C. Crick, A Structure for Deoxyribose Nucleic
Acid, 171 NATURE 737 (1953) (unveiling the twisted-helix DNA structure that
Watson and Crick discovered).
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On each side of the ladder are strands of deoxyribose, which is a
sugar, and some phosphate molecules.37 Connecting the sides of the
ladder is a nucleotide pair, referred to as a base pair.38 Nucleotides
consist of four different chemicals, each of which is referred to by a
VLQJOH OHWWHU DGHQLQH ³$´  JXDQLQH ³*´  WK\PLGLQH ³7´  DQG
F\WRVLQH ³&´ 39 In these base pairs, an A is always paired with a T,
while a G is always paired with a C.40 Each strand of DNA, split
down the middle of the ladder, can then be expressed as a sequence
identified by letters corresponding to each nucleotide in the
sequence.41 Found in this string of letters are certain three-letter
nucleotide sequences that code for the production of an amino acid,
the basic building blocks of proteins.42 These sequences are called
³FRGRQV´43 Codons work together to provide for the synthesis of
proteins.44
These cooperaWLQJ FRGRQV DUH FDOOHG ³H[RQV´45
However, exons are only a tiny fraction of the human genome and
are frequently not contiguous in the DNA sequence. 46, 47 It turns out
that most of the human genome is not responsible for the
programming of anything.48 These portions of DNA sequence that
GR QRW FRGH IRU DPLQR DFLG SURGXFWLRQ DUH FDOOHG ³LQWURQV´ ZKLFK
comprise over ninety-eight percent of the human genome.49
Human gene patents are written to claim the isolated strand of
DNA that contains a group of exons found to code for some trait that
37.See NATIONAL HUMAN GENOME RESEARCH INSTITUTE, supra note 34.
38.Jonah D. Jackson, Note, SOMETHING LIKE THE SUN: WHY EVEN
³,62/$7('$1'385,),('´*(1(6$5(352'8&762)1$785(, 89
TEX..L. REV. 1453, 1458 (2011).
39.NATIONAL HUMAN GENOME RESEARCH INSTITUTE, supra note 34.
40.Jackson, SUPRA NOTE 38, at 1458.
41. Id.
42. Id.
43. Id.
44. Id.
45. Id.
46.Anthony J. F. Griffiths et. al., MODERN GENETIC ANALYSIS
INTEGRATING
GENES AND GENOMES, at 302 (2d ed. 2002).
47.Jackson, SUPRA NOTE 38, at 1458.
48.OAK RIDGE NATIONAL LABORATORIES, supra note 31, at BB5.
49.Id. ³/HVVWKDQRIWKHJHQRPHFRGHVIRUSURWHLQV´ 
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may be commercially valuable.50 These patents are filed as
composition-of-matter patents claiming the actual, genomic DNA.51
The USPTO also granted patents claiming what is known as
complementary DNA, or cDNA.52 Complementary DNA is a
synthetically produced copy of DNA that contains only the active
exons of a gene.53 7KHSURFHVVXVHGWRFUHDWHF'1$LV³ZHOONQRZQ
LQ WKH ILHOG RI JHQHWLFV´ DQG ³>R@QH VXFK PHWKRG EHJLQV ZLWK D
messenger RNA molecule, a naturally occurring ribonucleic strand
that contains only exons, and uses [it] to create a new, synthetic DNA
PROHFXOH´54
III.

GENE PATENTS IN THE UNITED STATES

The history of gene patents in the United States starts in 1973. 55 In
that year, the USPTO issued the first patent that included DNA as an
element of the claimed material.56 Later that same year, the USPTO
issued a patent that claimed a gene as an element in the production of
commercial hybrid maize.57 In 1982, the USPTO granted the first
patent application directed to human and animal genes.58
The Supreme Court first addressed the validity of patents claiming
the genetic material of living beings in Diamond v. Chakrabarty.59
In that case, the USPTO denied a patent application claiming a
bacterium that was created through the combined DNA of four other
microbes.60 The application was denied because, at the time of the
application, it was thought that claims to living things were not pa-

50.See generally Jackson, supra note 38 (discussing the isolation and purification
doctrine as it relates to the patenting of genes as compositions of matter).
51.Id. at 1453.
52.See generally Myriad Genetics, Inc., 133 S.Ct. 2107.
53.Id. at 2112.
54. Id.
55.Torrance, supra note 32, at 176.
56. Id.
57. Id.
58.Id. at 176-77 FODLPLQJD³>U@HFRPELQDQW DNA vector[s] comprising specified
QXFOHRWLGHVHTXHQFHVRIFRGRQVIRUµKXPDQFKRULRQLFVRPDWRPDPPRWURSLQ¶DQG
µWKHJURZWKKRUPRQHRIDQDQLPDOVSHFLHV¶UHVSHFWLYHO\´ 
59.See generally Diamond v. Chakrabarty, 447 U.S. 303 (1980).
60. Id.

2016

A MYRIAD OF REASONS

9

tentable subject matter.61 In the opinion in Chakrabarty, Chief
Justice Burger wrote to remind the USPTO that it and the courts
³VKRXOG QRW UHDG LQWR WKH SDWHQW ODZV OLPLWDWLRQV DQG FRQGLWLRQV
ZKLFK WKH OHJLVODWXUH KDV QRW H[SUHVVHG´62 The Court determined
that by its terms, the subject matter requirement of § 101 of the
Patent Act was expansive in nature.63 This determination was based
on the terminology used to define patentable subject matter, which
XVHV WKH JHQHULF WHUPV ³PDQXIDFWXUH´ DQG ³FRPSRVLWLRQ RI PDWWHU´
WKDW³SODLQO\FRQWHmplate[] that the patent laws would be given wide
VFRSH´64 Taking that reading of the Patent Act even further, the
&RXUW DQQRXQFHG WKDW WKH VFRSH RI SDWHQWDEOH VXEMHFW PDWWHU ³
LQFOXGH>V@DQ\WKLQJXQGHUWKHVXQWKDWLVPDGHE\PDQ´65
The key to that holding, and why the challenge to the particular
patent in question was made, turned on whether the genetically
modified bacterium engineered to eat oil claimed in the patent was a
³SURGXFWRIQDWXUH´´66 The Court made clear that the products and
laws of nature are not patentable subject matter:
The laws of nature, physical phenomena, and abstract ideas
have been held not patentable. Thus, a new mineral
discovered in the earth or a new plant found in the wild is not
patentable subjecWPDWWHU³6XFKGLVFRYHULHVDUH
manifestations of . . . nature, free to all men and reserved
H[FOXVLYHO\WRQRQH´67
However, the Court concluded that the bacterium in question was not
a product of nature because the organism was only in existence due
to the machinations of man, not nature.68 Therefore, the patent
application claiming the bacterium was acceptable under the
61.Id.; Ricki Lewis, A Brief History of DNA Patents, DNA SCIENCE BLOG (June
20, 2013), http://blogs.plos.org/dnascience/2013/06/20/a-brief-history-of-dnapatents/, archived at http://perma.cc/JQN7-22P2.
62.Chakrabarty, 447 U.S. at 308 (quoting United States v. Dubilier Condenser
Corp, 289 U.S. 178 (1933)).
63.Id. at 308-09 (1980).
64.Id. at 308.
65.Id. at 309 (citations omitted).
66.Id. at 306.
67.Id. at 309 (citations omitted).
68. Id.
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expansive reading of patentable subject matter announced by the
Court.69
After the Chakrabarty decision, the USPTO began granting many
of the gene patent applications it received, eventually including
patents claiming human genes.70 By 2005, the USPTO had issued
patents granting exclusive rights to some 4,382 of the 23,688 genes
that comprise the human genome.71 That is nearly twenty percent of
the human genome that was reserved exclusively to their respective
patent holders.72 The decision of the United States Supreme Court in
Myriad put an end to the issuance of patents claiming naturally
occurring DNA.73 However, it did leave intact the patents issued
claiming cDNA and will allow future patent applications directed
toward cDNA.74
IV.

THE CONTROVERSY OF GENE PATENTS

Beginning with the first gene patent issued, there has been a fiery
debate about the propriety of gene patents.75 Innovators have
supported gene patents as a means to ensure that their research
investment will be recouped.76 Opponents claim that gene patents
violate patent law, the Constitution, and are against public policy as
they allow corporDWHLQWHUHVWVWRPRQRSROL]HSHRSOH¶VDFFHVVWRWKHLU
own genetic information.77 Part IV details the claims on both sides
of the debate to frame it as a legal, business, and social issue.

69. Id.
70.Torrance, supra note 32, at 176.
71.Kyle Jensen & Fiona Murray, supra note 8, at 239-240.
72.Some quick math would reveal that the amount of the human genome that had a
patent claiming it by 2005 was 18.5%.
73.See generally Myriad Genetics, Inc., 133 S.Ct. 2107.
74.See id.
75.See generally BRCA FAQs, AMERICAN CIVIL LIBERTIES UNION,
https://www.aclu.org/free-speech/brca-faqs (last visited Oct. 10, 2014), archived at
http://perma.cc/3FQ6-VZDF.
76.See infra notes 118-138 and accompanying text.
77.See infra notes 78-117 and accompanying text.
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Opposition to Gene Patents
1.

Legal Arguments

The opposition to gene patents comes from many groups who have
various legal and social concerns regarding the propriety of these
patents.78 The groups who oppose these patents include medical
professionals, civil rights advocates, the American Association of
Retired PersRQV WKH³$$53´ DQGWKH6RXWKHUQ%DSWLVW&RQYHQWLRQ
to name a few. 79
Legal arguments claiming that DNA in molecular form should not
be patent eligible subject matter under 35 U.S.C. § 101 were the most
pervasive arguments of many opponents made in public statements
and in various amicus briefs filed in support of AMP and the plaintiffs.80 The plaintiffs and their amicus made an argument under §
101 that isolated-gene patents should be considered a product of
nature, and, as discussed above, should not be eligible for patent
protection.81
Regarding the § 101 issue, the AARP in its amicus brief to the
)HGHUDO &LUFXLW DUJXHG WKDW ³'1$ PROHFXOHV DQG KXPDQ JHQHV DUH
natural phenomena that when discovered are not the kind of
µGLVFRYHU\¶WKDW6HFWLRQZDVGHVLJQHGWRSURWHFW´82 In its federal
circuit amicus brief, the AARP cited American Wood-Paper Co. v.
78.SeeAMERICAN CIVIL LIBERTIES UNION supra note 75.
79.See Myriad Genetics, Inc. 133 S. Ct. at 2107.. (Plaintiff is the Association of
Molecular Pathology, a group of clinical and research pathologists); see also Brief
of Amici Curiae American Medical Association, et al, in Support of Petitioners,
$VV¶QIRU0ROHFXODU3DWKRORJ\Y0\ULDG*HQHWLFV,QF6&W  
(No. 12-398), 2013 WL 390998; Brief for AARP as Amici Curiae Supporting
3HWLWLRQHUV$VV¶QIRU0ROHFXODU3DWKRORJ\Y8QLWHG6WDWHV3DWHQWDQG7UDGHPDUN
Office, 689 F.3d 1303 (Fed. Cir. 2011) (No. 2010-1406), 2011 WL 585711. Brief
IRUWKH6RXWKHUQ%DSWLVW&RQYHQWLRQDV$PLFL&XULDH6XSSRUWLQJ3HWLWLRQHUV$VV¶Q
for Molecular Pathology v. United States Patent and Trademark Office, 653 F.3d
1329 (Fed. Cir. 2011) (No. 2010-1406), 2011 WL 585712;AMERICAN CIVIL
LIBERTIES UNION, supra note 75.
80.See generally Myriad Genetics, Inc., 133 S. Ct. 2107.
81.See generally id.
82.%ULHIIRU$$53DV$PLFL&XULDH6XSSRUWLQJ3HWLWLRQHUV$VV¶QIRU0ROHFXODU
Pathology v. United States Patent and Trademark Office, 653 F.3d 1329 (Fed. Cir.
2011) (No. 2010-1406), 2011 WL 585711, at *2.
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Fiber Disintegrating Co., 90 U.S. 566 (1874), to analogize the
LVRODWLRQ RI '1$ WR WKDW RI ³UHPRYLQJ SXOS IURP VWUDZ ZRRG RU
RWKHUQDWXUDOVRXUFHV´83 In American Wood-Paper Co., the Supreme
&RXUW KHOG WKDW ³Perely removing pulp from straw, wood, or other
natural sources did not make it a patentable new composition of
PDWWHUµ$SURFHVVWRREWDLQLW>DQH[WUDFW@IURPDVXEMHFWIURPZKLFK
it has never been taken may be the creature of invention, but the thing
LWVHOIZKHQREWDLQHGFDQQRWEHFDOOHGDQHZPDQXIDFWXUH¶´84 Thus,
WKH WKUXVW RI WKH $$53¶V   DUJXPHQW LV WKDW ³>V@LPLODUO\
isolating a gene . . . from the human body does not then make the
>JHQH@LWVHOISDWHQWDEOH´85
Additionally, the ACLU pointed to language in Chakrabarty that
also suggested human genes never should have been allowed to be
patented.86 The ACLU considers that the passage from Chakrabarty
quoted above necessarily implies that human genes should not have
been patentable.87 The DUJXPHQWJRHVPXFKOLNHWKH$$53¶V
argument: genes are analogous to a mineral or plant discovered in the
wild and merely isolating them is not enough to make them patent
eligible subject matter.88
2.

Social Policies

Many of the arguments opponents made against allowing human
genes to be patented were made in regards to the social implications
of gene patents.89 These concerns include restricting access to
second opinions, discouraging genetic testing due to cost, and the
potential to impede further research into the connections between
certain gene sequences and disease states.90 Opponents have also

83.Id. at *3 (citing Wood Paper Patent, 90 U.S. 566 (1874)).
84.Id. (quoting Wood Paper Patent, 90 U.S. 566 (1874)).
85. Id.
86.AMERICAN CIVIL LIBERTIES UNION, supra note 75.
87.See supra note 67 and accompanying text; AMERICAN CIVIL LIBERTIES UNION,
supra note 75.
88.AMERICAN CIVIL LIBERTIES UNION, supra note 75.
89.See infra notes 90-111 and accompanying text.
90.See generally AMERICAN CIVIL LIBERTIES UNION, supra note 75.
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claimed a moral, ethical, or religious disapproval regarding the
patenting of genes.91
a.

Patient care

In its amicus brief to the Federal Circuit, the AARP succinctly
VXPPHGXSWKHSULPDU\FRQFHUQVUHODWHGWRSDWLHQWFDUH,W³XUJ>HG@
the Court to find the [BRCA patents] invalid . . . [because] patents
such as [these] prohibit diagnosis and treatment based on second
medical opinions and discourage full medical testing . . . [along with]
DOVR VLJQLILFDQWO\ HOHYDW>LQJ@ WKH FRVW RI JHQHWLF WHVWLQJ´92 These
assertions by the AARP are indicative of the opinion of many
opponents of gene patents.93
As the AARP pointed out, patient care was often foremost among
the social policy concerns of gene patent opponents.94 Thanks to the
exclusivity granted to patent holders, gene patent holders could
UHVWULFWRWKHUFRPSDQLHVIURPUXQQLQJGLDJQRVWLFVWRDQDO\]HSDWLHQWV¶
genetic makeup.95 In effect, this leaves patients without any access
to a second opinion as to the diagnosis made by the patent holder
genetic diagnostics laboratory, unless that patent holder agrees to
license the gene patent or allow other laboratories to test for the
individual gene that may indicate whether a patient is more likely to
develop some disease.96 To illustrate this concern, opponents point
to several cease and desist letters Myriad Genetics sent to university

91.See generally Audrey R. Chapman, Religious Contributions to the Debate on
the Patenting of Human Genes, 10 U. ST. THOMAS L.J. 650 (2013).
92.Brief for AARP as Amici Curia Supporting Petitioners, supra note 82, at 2.
93.See generally Eric Hoffman, Why Gene Patents Are Bad for Patients and Science, THE AMERICAN INTEREST (Aug. 9, 2011), http://www.the-americaninterest.com/articles/2011/8/9/why-gene-patents-are-bad-for-patients-andscience/#sthash.MDvyTHBH.dpuf[http://perma.cc/FR5T-FMT6].
94.Brief for AARP as Amici Curiae Supporting Petitioners, supra note 82, at 3-4.
95.Karuna Jaggar, Ruling to Overturn Human Gene Patents is a Huge Win For
:RPHQ¶V+HDOWK, GENEWATCH,
http://www.councilforresponsiblegenetics.org/GeneWatch/GeneWatchPage.aspx?p
ageId=474, archived at http://perma.cc/6DFV-KCG3 (last visited Oct. 10, 2014).
96. Id.
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researchers who were testing for the BRCA genes in their not-forprofit clinical laboratories.97
Gene patents could have also prevented the development of better
and less expensive testing for patented genes due to the threat of
infringement litigation.98 In a survey of genetic research labs,
upward of fifty percent of those labs reported that the possibility of
infringement actions concerning patented genes led them to
discontinue research into some genes.99
Gene patents may also have provided physicians with incentives to
violate the doctor-patient relationship.100 One illustration of this can
be found in the story of a businessman from Washington. 101 John
Moore was diagnosed with hairy-cell leukemia.102 For treatment, he
travelled from his home in Seattle, Washington to the UCLA Medical
Center, where he was the patient of a top specialist in Oncology.103
+LVGRFWRURUGHUHGWKHUHPRYDORI0RRUH¶VVSOHHQDQGYDULRXVRWKHU
treatments.104
After treatment and surgery, Moore continued to travel to and from
Los Angeles for the next seven years for continued testing.105 Moore
thought he was being monitored for potential relapse and
reappearance of his leukemia.106 What actually was happening
bordered on the? His physician was filing patents that claimed unique
FRPSRXQGVLQ0RRUH¶VEORRGDSDWHQWthat claimed one isolated gene
RI 0RRUH¶V DQG ZDV DOVR HQWHULQJ FRQWUDFWV WR GHYHORS D FHOO OLQH
XVLQJ 0RRUH¶V WLVVXH107 One contract with a pharmaceutical

97.E. Richard Gold & Julia Carbone, Myriad Genetics: In the Eye of the Policy
Storm, 12 GENETICS MED., S39, S39 ± S70 (2010).
98.Hoffman,supra note 93.
99.Mildred K. Cho et al, Effects of Patents and Licenses on the Provision of Clinical Genetic Testing Services, 5 J. MOLECULAR DIAGNOSTICS 3, 7 (February 2003).
100.See infra notes 101-11 and accompanying text.
101.See Moore v. Regents of the Univ. of Cal., 793 P.2d 479, 480-81 (Cal. 1990).
102.Id.
103.Id.
104.Id.
105.Id.
106.Id.
107.Id. at 481-482.
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company who wished to develop the cell line (named the Mo-cell
line, after John Moore) was purportedly worth $15 million dollars.108
0RRUHVDLGDERXWWKHLQFLGHQW³:KDWWKHGRFWRUVKDGGRQHZDVWR
claim that my humanity, my genetic essence, was their invention and
their property. They view me as a mine from which to extract
biological material , ZDV KDUYHVWHG´109 As a result of this
mistreatment, Moore filed a suit that was dismissed primarily for its
XQXVXDO QDWXUH EXW 0RRUH¶V FDVH ZDV HYHQWXDOO\ KHDUG DQG WKH
California Court of Appeals ruled in his favor.110 However, the
California Supreme Court eventually found that he had no property
right in the patents and products derived from him, but only that he
KDGPHULWRULRXVFODLPVDVWRWKHEUHDFKRIWKHUHVHDUFKHU¶VILGXFLDU\
duty to Moore and a failure of informed consent.111
b.

Religious objections to gene patents

Various religious figures and organizations have also been vocal
opponents of gene patents.112 Their concerns with gene patents are
not a unitary, monolithic voice, but have provided some viewpoints
into the debate beyond the concerns for patients and the technical,
scientific, and legal arguments against gene patents.113
Religious groups have raised concerns that the patenting of life
IRUPVDQGWKHLUJHQHWLFFRGH³LPSOLHVWKDWKXPDQEHLQJVUDWKHUWKDQ
*RG DUH WKH LQYHQWRUV RI WKHVH IRUPV RI OLIH´114 This sentiment
echoes the scientific argument against gene patents that the
discoverers of valuable gene sequences are not actually inventing
anything and, accordingly, should not be granted patent protection.115
A large group of faith-based organizations, which included
Protestant, Catholic, Orthodox, Jewish, Muslim, Buddhist, and Hindu
108.Id. at 482
109.John Vidal & John Carvel, Lambs to the Gene Market, THE GUARDIAN (LonGRQ 1RYDW TXRWLQJ-RKQ0RRUHVD\LQJKHZDV³HVVHQFH-UDSHG´ 
110.Moore, 793 P.2d at 502
111.Id. at 497.
112.See generally Audrey Chapman, supra note 91.
113.See generally id.
114.Id. at 668.
115.Rebecca S. Eisenberg, Why the Gene Patenting Controversy Persists, 77
ACAD. MED., 1381, 1384.
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denominations, joined together to form the Joint Appeal Against
Human and Animal Patenting.116 They released the following joint
statement:
We, the undersigned religious leaders, oppose the patenting of
human and animal life forms. We are disturbed by the U.S. Patent
2IILFH¶V UHFHQW GHFLVLRQ WR SDWHQW KXPDQ ERG\ SDUWV DQG VHYHUDO
genetically engineered animals. We believe that humans and animals
are creations of God, not humans, and as such should not be patented
as human inventions.117
B.

Proponents of Gene Patents

1.
Legal Arguments
Proponents of gene patents alleged that, as patented, genes were
not products of nature.118 This argument flows from the fact that
composition of matter patents had been granted to substances that
were isolated and purified from their source.119 Judge Learned Hand,
in Parke-Davis & Co. v. H.K. Mulford Co., explained the isolation
and purification doctrine.120 In that case, the patentee had claimed
ownership over the chemical compound adrenaline.121 By claiming
the chemical, the patentee was able to exert exclusivity over a
chemical compound that occurs naturally in all people122
He was able to do so because, as Judge Hand found, the claimed
substance was different in chemical compound, due to its separation
from the gland producing it, and because of its therapeutic effect,
which results from the concentration of the chemical and the removal
116.Chapman, supra note 91 at 662-63.
117.Joint Appeal Against Human and Animal Patenting, text of the press conference announcement made available by the General Board of Church and Society of
the United Methodist Church, Washington, D.C. (May 17, 1995).
118.Kevin Noonan, Why Genes Must Remain Eligible For Patenting, GENEWATCH
http://www.councilforresponsiblegenetics.org/GeneWatch/GeneWatchPage.aspx?p
ageId=304&archive=yes, archived at http://perma.cc/7C3S-PKED.
119.See generally Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95 (S.D.N.Y.
1911); see also Merck & Co v. Olin Mathieson Chemical Corp, 253 F.2d 156 (4th
Cir. 1958).
120.See Parke-Davis & Co. at 103.
121.Id. at 95.
122.Id.
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of other substances.123 Judge Hand described the differences made
E\LVRODWLQJDQGSXULI\LQJDGUHQDOLQHDVDGLIIHUHQFH³QRWLQGHJUHH
EXW LQ NLQG´124 Thus, the isolation and purification doctrine of
chemical compound patents allows for the patenting of some
naturally occurring substances after all.125
-XGJH+DQG¶VDQDO\VLVEROVWHUVWKHDUJXPHQWRISURSRQHQWVRIJHQH
patents by the fact that mosWJHQHWLFVHTXHQFHFRQWDLQSULPDULO\³MXQN
'1$´DVGHWDLOHGLQ3DUW,,DQGQHFHVVDULO\UHTXLUHLVRODWLRQRIWKH
active exon to be useful in a laboratory setting. 126 Furthermore, to be
XVHIXO E\ GLDJQRVWLFV FRPSDQLHV JHQH VHTXHQFHV DUH ³SXULILHG´ E\
removiQJWKH³MXQN´DQGFUHDWLQJF'1$127 However, the claim that
cDNA is the more useful version of the gene sequence seems to
ignore the fact that innovator labs largely held patents that claimed
the naturally occurring genomic DNA that are the source for
cDNA.128
There is also the fact that to disallow the patenting of genes would
upset thirty years of patent policy in the United States. 129 The
potential for economic chaos for the industry in the absence of gene
patents was central to the argument.130 Proponents of gene patents
also pointed to the potential that, if human gene patents were invalid,
then it may be that any number of antibiotics, petroleum, and animal
products are ineligible for patent protection.131

123.Id. at 104.
124.Id. at 103.
125.See generally id. at 95. ;see also Merck & Co, 253 F.2d 156.
126.See OAK RIDGE NATIONAL LABORATORIES, supra note 31, at BB5
127.See supra notes 47 - 49 and accompanying text.
128.Andrew Pollack, After Patent Ruling, Availability of Gene Tests could Broaden, NEW YORK TIMES, June 13, 2013,
http://www.nytimes.com/2013/06/14/business/after-dna-patent-ruling-availabilityof-genetic-tests-could-broaden.html?pagewanted=all&_r=0, archived at
http://perma.cc/RL53-MQY4.
129.$VV¶QIRU0ROHFXODU3DWKRORJ\Y86372, 702 F. Supp. 2d 181, 220 (S.D.N.Y.
2010).
130.Noonan, supra note 118.
131.Id.
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Research Incentive

The proponents of gene patents also refute the idea that gene
patents create a monopolization of genetic information by inhibiting
researchers other than the patent holder from conducting research.132
Kevin Noonan, a partner at McDonnel Boehnen Hulbert & Berghoff
LLP, claims that the opposite may in fact be the case. 133 He points to
the increase in the number of basic research reports on the genes in
question in Myriad (BRCA1 and BRCA2) since the patents claiming
the genes were issued.134 As well, Noonan cites to multiple studies
FRQGXFWHGLQWKHHDUO\¶VLQWKH8QLWHG6WDWHV$XVWUDOLD-DSDQ
and Germany that indicate gene patents rarely affect the research of
academic scientists.135
Noonan goes on to claim that the patent incentive has actually
encouraged private research companies to accelerate their research
into genetics.136 The result of such acceleration may very well be an
increase in the rate of discovery of the genetic markers that indicate
DQLQGLYLGXDO¶VSRWHQWLDOWRGHYHORSFHUWDLQ diseases.137 He and other
proponents of gene patents argue that when research is competitive
then patients win in the end, because knowledge of their genetic
information and the possibility of a more quickly available diagnostic
or treatment results in better outcomes for them.138
V.

MYRIAD: FROM NEW YORK TO D.C.

The primary legal issue in dispute in the string of Myriad decisions
was whether isolated genomic and complementary DNA sequences
were patentable subject matter under § 101 of the United States
Patent Act.139 There were also several method claims involved in the
lower court proceedings, which are not relevant to the discussion of
132.Id.
133.Id.
134.Id.
135.Id.
136 Id.
137.Id.
138.Id.
139.See $VV¶QIRU0ROHFXODU3DWKRORJ\Y86372)6XSSG 6'1<
2010).
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the gene patents, as those patents concerned various methods by
which Myriad was determining whether a potential therapeutic agent
was effective in treating cancer.140 Those method patents will be
discussed in Part VI.
The case that eventually reached the Supreme Court began in
federal district court in the Southern District of New York.141 The
district court decided in favor of the plaintiff and issued an opinion
LQYDOLGDWLQJ0\ULDG¶VSDWHQWVDVVXEMHFWPDWWHUXQSDWHQWDEOHXQGHU
101 of the Patent Act.142 Myriad appealed to the United States Court
RI $SSHDOV IRU WKH )HGHUDO &LUFXLW WKH ³)HGHUDO &LUFXLW´  ZKLFK
reveUVHGWKHORZHU FRXUWGHFLVLRQDQGKHOG WKDW 0\ULDG¶VSDWHQWV RQ
the BRCA1 and BRCA2 gene were valid as to both genomic and
complementary DNA.143 Upon a writ of certiorari, the Supreme
Court of the United States heard the case. In a unanimous opinion
penned by Justice Thomas, the Court reversed the Federal Circuit in
part and affirmed in part.
A.

Southern District of New York

³7KHLQTXLU\LQWRDQLQYHQWLRQ¶VSDWHQWHOLJLELOLW\LVDIXQGDPHQWDO
RQHDQGDVVXFKµWKHREOLJDWLRQWRGHWHUPLQHZKDWW\SHRIGLVFRYery
is sought to be patented must precede the determination of whether
WKDW GLVFRYHU\ LV LQ IDFW QHZ RU REYLRXV¶´144 This is merely a
statement of the § 101 standard that patent eligibility is the threshold
140.See id.
141.See id.
142.See id.
143.$VV¶QIRU0ROHFXODU3DWKRORJ\Y863DWHQW Trademark Office, 653 F.3d
1329, 1358 (Fed. Cir. 2011); see also $VV¶QIRU0ROHFXODU3DWKRORJ\Y8QLWHG
States Patent and Trademark Office, 689 F.3d 1303, 1337 (Fed. Cir. 2012) (afILUPHGFRXUW¶VGHFLVLRQWRH[HUFLVHGHFODUDWRU\MXGJPHQWMXULVGLFWLRQRYHU this case,
UHYHUVHGWKHGLVWULFWFRXUW¶VJUDQWRIVXPPDU\MXGJPHQWZLWKUHJDUGWR0\ULDG¶V
FRPSRVLWLRQFODLPVWRLVRODWHG'1$VDQGDIILUPHGWKHGLVWULFWFRXUW¶VJUDQWRI
VXPPDU\MXGJPHQWZLWKUHJDUGWR0\ULDG¶VPHWKRGFODLPVGLUHFWHGWRFRPSDULQJ
or analy]LQJJHQHVHTXHQFHVDQGUHYHUVHGWKHGLVWULFWFRXUW¶VJUDQWRIVXPPDU\
MXGJPHQWZLWKUHJDUGWR0\ULDG¶VPHWKRGFODLPWRVFUHHQLQJSRWHQWLDOFDQFHU
therapeutics via changes in cell growth rates of novel, man-made transformed
cells).
144.$VV¶QIRU0ROHFXOar Pathology, 702 F. Supp. 2d at 219 (quoting Parker v.
Flook, 437 U.S. 584, 593 (1978)).
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question regarding the validity of a patent and must be answered
before continuing on to other legal matters regarding the patent in
question.145 The District Court determined that the question regarding
0\ULDG¶V %5&$ JHQH SDWHQWV ZDV ³ZKHWKHU WKH FODLPHG
compositions and methods constitute statutory subject matter or fall
within the judicially created products of nature exception to
SDWHQWDEOHVXEMHFWPDWWHU´146
)LUVWWKHFRXUWGLVPLVVHG0\ULDG¶VLQLWLDOGHIHQVHVWRWKHFODLPRI
ineligibility.147 0\ULDG¶VILUVWDUJXPHQWZDV that the court should not
look to invalidate their gene patents on the grounds that the
³µFDUHIXOO\FRQVLGHUHGSROLF\RIWKH86372¶LVµHQWLWOHGWRJUHDW
UHVSHFW IURP WKH FRXUWV¶´ EDVHG RQ WKH SUHVXPSWLRQ RI YDOLGLW\ RI
SDWHQWV DQG WKH 86372¶V consideration of the eligibility of gene
patents.148 This argument did not sway the court and it pointed to a
)HGHUDO &LUFXLW GHFLVLRQ LQ VD\LQJ WKDW ³>WKDW FRXUW@ KDV SUHYLRXVO\
KHOG WKDWLWRZHV QRGHIHUHQFHWR 86372OHJDO GHWHUPLQDWLRQV´DQG
WKDW ³>Whe] court reviews statutory interpretation . . . without
GHIHUHQFH´149
7KH FRXUW¶V DQDO\VLV SURYLGHG WKDW 0\ULDG¶V JHQH SDWHQWV DV
FODLPHGKDGQR ³PDUNHGO\GLIIHUHQW FKDUDFWHULVWLFV´IURPDSURGXFW
RI QDWXUH GHVSLWH 0\ULDG¶V DVVHUWLRQ WKDW WKH isolation of the DNA
molecules should render them patentable.150 Focusing on the nature
of DNA, the court determined that regardless of whether the DNA is
native or isolated its primary function is to carry genetic
information.151 Due to this functional concern, the Court decided
LVRODWHG '1$ GRHV QRW KDYH WKH UHTXLVLWH ³GLIIHUHQW FKDUDFWHULVWLFV´

145.See In re %LOVNL)G )HG&LU  HQEDQF  ³:KHWKHUD
claim is drawn to patent-eligible subject matter under § 101 is a threshold inquiry,
and any claim of an application failing the requirements of § 101 must be rejected
HYHQLILWPHHWVDOORIWKHRWKHUOHJDOUHTXLUHPHQWVRISDWHQWDELOLW\´ 
146.$VV¶QIRU0ROHFXODU3DWKRORJ\, 702 F. Supp. 2d at 220.
147.Id.
148.Id.
149.Id. at 221 (quoting Arnold 3¶VKLSY'XGDV)G )HG&LU
2004)).
150.$VV¶QIRU0ROHFXODU3DWKRORJ\, 702 F. Supp. 2d at 227-228.
151.Id. at 227-229.
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to allow patentability.152 0\ULDG¶V F'1$ FODLPV ZHUH DOVR IRXQG
LQYDOLGGXHWRWKHFRXUW¶VGHWHUPLQDWLRQWKDWGHVSLWHFRQWDLQLQJRQO\
exons, cDNA is QRW³PDUNHGO\GLIIHUHQW´IURPQDWLYH'1$153
Myriad also asserted that the invalidation of their patents would
FRPSULVHDQXQFRQVWLWXWLRQDOWDNLQJZKLFKWKHFRXUWFDOOHG³QRYHO´
EXW³XQSHUVXDVLYH´154 7KLVZDVDOVRWKH&RXUW¶VDQDO\VLVFRQFHUQLQJ
0\ULDG¶V Sroposition that invalidating the patents would be in
violation of the treaty obligations of the United States as embodied in
the Agreement on Trade-Related Aspects of Intellectual Property
5LJKWV ³75,36´ 155
B.

The Federal Circuit: Round One

On appeal, the Federal Circuit affirmed the District Court in part
and reversed the District Court in part.156 The Federal Circuit
DIILUPHG WKH ORZHU FRXUW¶V GHFLVLRQV UHJDUGLQJ WKH PHWKRGV SDWHQWV
and reversed the decisions on the composition patents, which it found
were directed to patent eligible subject matter as to both the native
DNA and cDNA claims.157 In finding that the composition of matter
patents was valid, the court relied on the totality of the differences
between native DNA and isolated DNA, rather than the more strict
functionally informational approach the District Court used.158
However, the Federal Circuit had the chance to hear the case again
when the Supreme Court granted certiorari and remanded the case
back to the court to review its decision in light of the Supreme
152.Id. DW ³%HFDXVHWKHFODLPHGLVRODWHG'1$LVQRWPDUNHGO\GLIIHUHQWIURP
native DNA as it exists in nature, it constitutes unpatentable subject matter under
86&´ 
153.Id. at 230.
154.Id. 221- ³0\ULDG¶VQRYHOWDNLQJVDUJXPHQWUXQVFRXQWHUWRDORQJKLVWRU\
RILQYDOLGDWLRQSDWHQWFODLPVE\WKHFRXUWVDQGLVXQVXSSRUWHGE\OHJDOSUHFHGHQW´ 
155.Id. ³$rticles 8.1 and 27.3 of TRIPS permit governments to incorporate public
health concerns into their intellectual property laws and to exclude from patentability diagnostic, therapeutic, or surgical methods as well as particular inventions on
the grounds of pXEOLFLQWHUHVW´ 
156.$VV¶QIRU0ROHFXODU3DWKRORJ\, 653 F.3d at 1358.
157.Id.
158.Id. at 1350- ³>,@WLVWKHGLVWLQFWLYHQDWXUHRI'1$PROHFXOHVDVLVRODWHG
compositions of matter that determines their patent eligibility rather than their
physiological XVHRUEHQHILW´ 
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&RXUW¶V GHFLVLRQ LQ Mayo Collaborative Services v. Prometheus
Laboratories, Inc.159
C.

The Federal Circuit: Round Two

On remand, the Federal Circuit maintained its position regarding
all the claims in question.160 However, in this decision the court
made a definitive statement on the patent eligibility of cDNA.161 The
FRXUWKHOGWKDW³WKHFODLPHGF'1$VDUHHVSHFLDOO\GLVWLQFWLYHODFNLQJ
the non-coding introns present in naturally occurring chromosomal
DNA. They are even more the result of human intervention into
nature and are hence patent-HOLJLEOHVXEMHFWPDWWHU´162
D.

The Supreme Court

In June 2013, the Supreme Court delivered an opinion that
LQYDOLGDWHG0\ULDG¶VJHQHSDWHQWVDQGDOORWKHUJHQHSDWHQWVFODLPLQJ
native or genomic DNA, but maintained the validity of cDNA
patents.163
The Court sided with the District Court in determining that the
native DNA patents were invalid due to their functionally
informational value as demonstrated by the claims in the patents
³IRFXV RQ WKH JHQHWLF LQIRUPDWLRQ HQFRGHG LQ WKH >JHQHV@´164 On
cDNA, the Court clarified that cDNA patents remain valid as
patentable subject matter because of the fact that human intervention
is required to make the molecule.165
The Court specifically addressed issues that were not implicated in
its decision, which reveal some means by which innovator research
159.$VV¶QIRU0ROHFXODU3DWKRORJ\Y8QLWHG6WDWHV3DWHQWDQG7UDGHPDUN2IILFH
132 S.Ct. 1794 (Memo) (2012); see Mayo Collaborative Services v. Prometheus
Laboratories, Inc., 132 S.Ct. 1289 (2012) (concerning the validity of certain methods patents).
160.$VV¶QIRU0ROHFXODU3DWKRORJ\, 689 F.3d at 1337.
161.Id. at 1329.
162.Id.
163.Myriad Genetics, Inc.6&WDW ³:HPHUHO\KROGWKDWJHQHVDQGWKH
information they encode are not patent eligible under § 101 simply because they
have beHQLVRODWHGIURPWKHVXUURXQGLQJJHQHWLFPDWHULDO´ 
164.Id. at 2118.
165.Id. at 2119.
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and diagnostics labs may still have some patent claims to their
discoveries.166 Justice Thomas specifically noted that certain types of
method claims might still be patentable.167 Additionally, patents that
LQYROYH ³QHZ DSSOLFDWLRQV RI NQRZOHGJH DERXW    JHQHV´ DUH WR
remain patentable subject matter.168 Lastly, there is the possibility
that DNA in which the nucleotide order has been altered in some way
may be patent eligible subject matter.169
VI.

WHAT¶S LEFT: INCENTIVES FOR INNOVATION AND
COMPETITION POST-MYRIAD

As has been detailed above, there are various grounds on which
people and organizations opposed the patenting of human genes.170
Supporters generally relied upon not upsetting the status quo and the
argument that without gene patents there would remain little
incentive for crucial genetic research.171 There are no legitimate
parties arguing that research into the human genetic code and
discovering the connection between genetics, diseases, and potential
therapies is not a desirable course of action, but why should research
labs and diagnostics companies continue to fund such ventures
without the security afforded by gene patents? This Part of the Note
outlines several means by which innovators may still be incentivized,
including federal funding, other types of patents and patent protection
in other markets. Additionally, this Note suggests the adoption of a
proposed regulatory change that would have genetic diagnostics be
regulated by the FDA and would afford some exclusivity to innovator
labs under current regulatory exclusivity regimes.

166.Id.
167.Id.
168.Id.
169.Id. ³6FLHQWLILFDOWHUDWLRQRIWKHJHQHWLFFRGHSUHVHQWVDGLIIHUHQWLQTXLU\DQG
we express no opinion about the application of § 101 to such endeDYRUV´ 
170.See supra, Part III.
171.See supra Part III.
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Remaining Patent Protection
1.

cDNA Patents

The hROGLQJ LQ WKH 6XSUHPH &RXUW¶V GHFLVLRQ LQ Myriad leaving
intact the viability of cDNA patents is key to the remaining incentive
scheme for genetic researchers.172 Complementary DNA is generally
viewed as the more commercially viable form of DNA.173 This is
because cDNA is the more easily manipulated form of DNA that is
used to engineer plant, animal, and bacterial cells.174 In addition,
cDNA is the form of DNA used in most of the commercially
available diagnostics due to the ability to synthesize more of, and
thus amplify, the specific gene at which the diagnostic is targeted.175
However, a significant problem with continuing to rely on cDNA
patents for protection in the genetics field was not addressed by the
Supreme Court in Myriad. Due to the advanced state of genetics
technology and the widespread understanding of the process by
which cDNA is synthesized, cDNA patents may very well be
successfully challenged under § 103 for being obvious to a person
skilled in the art.176
2.

Methods Patents

Some types of patents are likely to remain viable in the genetics
field for quite some time, and were specifically singled out by the
Supreme Court as potential sources of patent protection for genetic
researchers.177 -XVWLFH7KRPDVH[SODLQHGWKDW³>K@DG0\ULDGcreated
an innovative method of manipulating genes while searching for the
BRCA1 and BRCA2 genes, it could possibly have sought a method
SDWHQW´178 Based on this guidance from the Court, innovator diagnostics companies may be secure in the knowledge that if they do
172.Myriad Genetics, Inc., 133 S.Ct. at 2119.
173.Pollack, supra note 128.
174.Id.
175.Gregory Dolin, Exclusivity Without Patents: The New Frontier of FDA
Regulation for Genetic Materials, 98 IOWA L. REV. 1399, 1415 (2013).
176.Id. at 1444; The obviousness problem with continuing to allow cDNA patents
cannot be understated.
177.Myriad Genetics, Inc., 133 S.Ct. at 2119.
178.Id.
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devise some novel method of gene manipulation, they will be able to
secure a patent for the innovation, so long as they can demonstrate
that the claimed innovation meets the necessary requirements of
patentability.
Furthermore, Myriad itself won a challenge to one of its method
SDWHQWV LQ WKH OLWLJDWLRQ OHDGLQJ XS WR WKH 6XSUHPH &RXUW¶V
decision.179 The method patent that was unsuccessfully challenged
concerned a method by which Myriad was determining the efficacy
of certain potential cancer treatments.180 The claimed innovation was
challenged on the basis that it was simply applying a law of nature
that cancer cells do not grow as well in the presence of an
oncological therapy.181 This challenge seemed to be a good
argument against the claimed method under the decision made by the
Supreme Court in Mayo Collaborative Services v. Prometheus
Laboratories, Inc.. ,Q WKDW FDVH WKH &RXUW ³LQYDOLGDWHG FODLPV
directed to the relationship between concentrations of certain
metabolites in the blood and the likelihood that a particular dosage of
D WKLRSXULQH GUXJ ZLOO EH RSWLPXP´182 7KH &RXUW KHOG WKDW ³WR
transform an unpatentable law of nature into a patent-eligible
application of such a law, one must do more than simply state the
ODZRIQDWXUHZKLOHDGGLQJWKHZRUGVµDSSO\LW¶´183
Using the Mayo standard, the Federal Circuit decided that Myriad
had supplied a sufficiently innovative step to avoid the natural law
problem.184 The rHDVRQLQJRIWKHFRXUWZDVWKDWRQFHD³FRPSRVLWLRQ
of matter is [determined to be] patent eligible subject matter,
applying various known types of procedures to it is not merely
DSSO\LQJFRQYHQWLRQDOVWHSVWRDODZRIQDWXUH´185
179.$VV¶QIRU0ROHFXODU3DWKRORJ\, 689 F.3d at 1309.
180.Id. at 1310.
181.Id. .
182.Id. at 1336 (quoting Mayo Collaborative Services v. Prometheus Laboratories,
Inc., 132 S. Ct 1289, 1294 (2012)).
183.Mayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S. Ct 1289,
1290 (2012).
184.$VV¶QIRU0ROHFXODU3DWKRORJ\, 689 F.3d at 1335-1336.
185.Id. DW ³7KHWUDQVIRUPHGPDQ-made nature of the underlying subject
matter in claim 20 makes the claim patent-eligible. The fact that the claim also
LQFOXGHVWKHVWHSVRIGHWHUPLQLQJWKHFHOOV¶JURZWKUDWHVDQGFRPSDULQJJURZWK
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However, despite its success on the aforementioned method claim,
Myriad has more recently been the victim of some method patent
invalidations at the hand of the Federal Circuit.186 In In re BRCA1,
the Federal Circuit invalidated a method claim for comparing a
persRQ¶V %5&$ VHTXHQFH ZLWK ZLOG-type BRCA sequences to
identify differences that may indicate an increased risk of breast
cancer.187 Additionally, the court invalidated another method claim
for some diagnostic methods used to identify mutations in BRCA
sequences, because the claimed steps and diagnostic methods did not
contain any new process, design, or use of diagnostic tests or
instruments.188
As can be seen in recent court decisions, there are certainly more
hurdles to successfully claiming a method in a patent.189 However,
the option is still available to genetic researchers and diagnostic
innovators if they can clear those hurdles.
3.

Gene Patent Protection Abroad

Despite no longer being able to patent naturally occurring genes in
the United States, innovator researchers and diagnostic companies
still have the option to apply for patent protection for discovered
genes in countries that allow for the patenting of such genes.190
Naturally occurring gene patents are still viable in at least three of the
largest healthcare markets in the world: the European Union, Japan,

rates does not change the fact that the claim is based on a man-made, non-naturally
occurring transformed cell²SDWHQWHOLJLEOHVXEMHFWPDWWHU´ 
186.In the time between the Mayo and Myriad decisions and this case, the Supreme
Court decided Alice Corp. v. CLS Bank ,QW¶O, 134 S.Ct. 2347 (2014), which reinforced a two-step test to determine patent eligibility for claims containing abstract
ideas; see In re BRCA1- and BRCA2- Based Hereditary Cancer Test Patent Litig.,
774 F.3d 755,756 (2014) (citing Alice to establish that the two-step test requires
identifying whether the claim contains an abstract idea and then determining
whether there are other items in the claim that may render it patent eligible despite
containing an abstract idea).
187.In re BRCA1- and BRCA2- Based Hereditary Cancer Test Patent Litig., 774
F.3d 755, 756 (2014).
188.Id. at 766.
189.See supra notes 177-188 and accompanying text.
190.See infra notes 191-204 and accompanying text.
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and Australia.191 There are also other countries in which gene patents
remain valid, but this Note only addresses the possibility of securing
gene patents in these three countries.192
7KH(XURSHDQ3DWHQW2IILFH ³(32´ DFWLQJXQGHUWKHMXULVGLFWLRQ
of the European Patent Organization, allows the patenting of genes
following the guidelines of European Union directive 98/44/EC (the
The Biotech Directive provides that
³%LRWHFK 'LUHFWLYH´ 193
³ELRORJLFDOPDWHULDOZKLFKLVLVRODWHGIURPLWVQDWXUDOHQYLURQPHQWRU
produced by means of a technical process may be the subject of an
LQYHQWLRQHYHQLILWSUHYLRXVO\RFFXUUHGLQQDWXUH´194 However, the
EPO will not grant patents directed to genes identified without an
identified function.195 Along with an identifiable function, the gene
PXVWDOVRKDYHDGLVFORVHG³LQGXVWULDODSSOLFDWLRQ´OLVWHGLQWKHSDWHQW
application.196
³,QGXVWULDO DSSOLFDWLRQ´ KDV KDG YDULRXV
interpretations applied to it, but a recent decision by the EPO
GHWHUPLQHG WKDW RQO\ D ³FRQFUHWH EHQHILW´ LV UHTXLUHG197 For
example, a gene shown to be usable in the cure or diagnosis of a
disease would be likely considered to have an immediate benefit to
industry even though it may be profitable for any use.198 A gene that
shows promise that future research will lead to such a practical
application will be insufficient to gain patentability. 199 This includes
191.See Infra notes 192-204 and accompanying text.
192.See generally Executive Summary: Genetics, genomics, and the patenting of
DNA, WORLD HEALTH ORGANIZATION, available at
http://www.who.int/genomics/publications/background/en/, archived at
http://perma.cc/4342-8HG3 (discussing the patenting of genes around the world
and noting that genes can be patented in India, China, and potentially Brazil).
193.Andrew Sharples, Gene Patents in Europe Relatively Stable Despite
Uncertainty in the U.S., GENETIC ENGINEERING & BIOTECHNOLOGY NEWS (Mar.
23, 2011), http://www.genengnews.com/insight-and-intelligenceand153/genepatents-in-europe-relatively-stable-despite-uncertainty-in-the-us/77899385/,archived at http://perma.cc/PP7W-HH9N.
194.Council Directive 98/44, art. 3, 1998 O.J. (L 213) 13,18.
195.Id. at 15.
196.Id. at 18.
197.Sharples, supra note 193.
198.Naomi Hawkins, Human Gene Patents and Genetic Testing in Europe: A
Reappraisal, 7:3 SCRIPTed 453, 461 (2010), http://www.law.ed.ac.uk/ahrc/scripted/vol7-3/hawkins.asp.
199.Id.
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any claims that are speculative as to possible future uses.200 Under
these guidelines, many of the genes that researchers and diagnostic
companies would have patented in the United States should remain
patentable in the European Union.
,Q  WKH -DSDQHVH 3DWHQW 2IILFH WKH ³-32´  LQFOXGHG as
patentable subject matter methods by which information can be
gathered from the human body.201 This guideline will clearly apply
to the patenting of genetic material that may indicate possible disease
states in a person.202 However, the claim to the gene or DNA
sequence must be carefully drawn to avoid including any step that
LQYROYHV MXGJPHQW GLDJQRVLV RU WUHDWPHQW RI D SHUVRQ¶V SK\VLFDO
VWDWHEHFDXVHWKHFODLPZLOOWKHQIDLOXQGHUWKH-32¶VUXOHVH[FOXGLQJ
FODLPVWR³PHGLFDODFWLYLW\´203
Finally, in Australia, courts that have had the opportunity to hear
challenges to gene patents have simply dismissed the cases, and the
higher courts have denied rehearing of the cases.204 As such, gene
patents are still viable in Australia.
B.

Academic Pursuits and Federal Funding

Regardless of patent protection, academic research facilities have
long been a bastion of scientific advancements. As evidence of this,
much of modern knowledge has been developed without any
incentive beyond the accumulation of raw knowledge about the
world, how it works, and ways in which humans can manipulate the
natural order in productive ways.
In light of the fruitfulness of academic research, the federal
government provides large amounts of funding for research into
various fields of study, including various forms of genetic
200.Id.
201.Kenji Sugimaura & Rebecca Chen, IPS Cell Technology Spurs Biological
Patenting in Japan, World Intellectual Property Review Annual 2013, at 66, 67
(2013), http://sugi.pat.co.jp/wp-content/uploads/2013/05/WIPR-2013Annual_Page_1.pdf, [http://perma.cc/BXJ5-5ZXV].
202.Id.
203.Id.
204.Heidi Ledford, Australian Gene-Patent Case Dismissed, NATURE NEWS
BLOG (SEP. 5, 2014, 18:46 BST), http://blogs.nature.com/news/2014/09/australiangene-patent-case-dismissed.html, archived http://perma.cc/F5TQ-J3Y4.
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research.205 In 2013, the National Institutes of Health reported that
federal funding for genetics research, including categories such as
³*HQH7KHUDS\´³*HQH7KHUDS\&OLQLFDO7ULDOV´³*HQHWLF7HVWLQJ´
DQGDEURDG³*HQHWLFV´FDWHJRU\H[FHHGHGHLJKWELOOLRQGROODUV206
Genetic diagnostic companies may decide that, without adequate
patent protection, that their business model may be better suited to
simply developing the actual diagnostics used to commercialize the
findings of academic researchers. This model would allow these
companies to funnel their former research costs into the development
of better diagnostics, which may lead to more commercial success
because they can focus on supplying the best product rather than
racing to find the next BRCA-W\SH³JROGPLQH´
C.

Regulatory Schemes

The FDA has the authority to regulate genetic tests, but does not
currently do so except for genetic test kits.207 Test kits are
diagnostics marketed as a commercial test sold directly to consumers
or labs other than the lab that developed the test.208 On the other
KDQGODERUDWRU\GHYHORSHGWHVWV ³/'7V´ DUHGLDJQRVWLFVGHYHORSHG
and performed by only the single innovator lab to which all specimen
samples, regardless of collection site, are sent for testing. 209 The
FDA does not currently regulate the validation or performance of
LDTs.210 However, the FDA has provided Congress with draft
guidelines on the regulation of LDTs.211 As no decisions have been
205.See generally Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC), NATIONAL INSTITUTES OF HEALTH (Feb. 5, 2015),
http://report.nih.gov/categorical_spending.aspx, archived at http://perma.cc/Z47VBNBK (describing the amount of money funneled into various areas of research).
206.Id.
207.Regulation of Genetic Tests, NATIONAL INSTITUTES OF HEALTH (Apr.
17, 2015), http://www.genome.gov/10002335, archived at http://perma.cc/EB7JMWPS.
208.Id.
209.Id.
210.Id.; See also Dolin, supra note 175, at 1456-57 (showing that validation means
the determination that a diagnostic test performs adequately the function for which
it was designed to be used).
211.See generally Laboratory Developed Tests, FOOD AND DRUG
ADMINISTRATION,
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made in regards to the full implementation of those guidelines, this
Note does not address the contents of those proposed guidelines.
However, this Note does propose that the FDA should extend their
current regulatory exclusivity scheme to cover LDTs and test kits and
provide an exclusivity-based incentive for genetic research. This
Note has identified one promising scheme proposed by Dr. Gregory
Dolin.
Gregory Dolin, M.D., proposes that an expansion in the law that
controls biologic drug products would help incentivize research into
genetic diagnostics even in the absence of patent claims. 212 He
proposes that the non-patent market exclusivity regime that is
currently in effect for biologic drug products could easily be
extended to include genetic diagnostics classified as either LDTs or
test kits.213 This kind of market exclusivity would not be a barrier to
research into or the development of new treatments or diagnostics
that use the same gene sequences because his proposed scheme
would only provide exclusivity to the marketer of tests intended to
treat, cure, or diagnose a targeted disease.214 Therefore, other
researchers may freely use the identified genes in developing their
own diagnostics or treatments for the same or other disease
associated with that specific genetic sequence.215 The application of
the regulatory exclusivity regime will determine when the innovator
will lose exclusivity, but FDA market exclusivity, which is variable
in length, is generally far shorter than the twenty years of control
granted by a patent.216
D.

Trade Secret

If the FDA declines to create or extend to LDTs some form of
regulatory exclusivity, diagnostics companies still have the option to
UHWDLQWKHLUWHVWUHVXOWVDVDIRUPRIWUDGHVHFUHW$WUDGHVHFUHWLV³>D@
formula, process, device, or other business information that is kept
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagn
ostics/ucm407296.htm, archived at http://perma.cc/47YG-JGJP.
212.Dolin, supra note 175, at 1406.
213.Id. at 1399-1400.
214.Id. at 1459.
215.Id.
216.Id. at 1460.
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confidential to maintain an advantage oYHU FRPSHWLWRUV´217
However, the Uniform Trade Secrets Act (UTSA) provides that to be
SURWHFWDEOH WKH LQIRUPDWLRQ PXVW QRW EH ³JHQHUDOO\ NQRZQ RU
DVFHUWDLQDEOH´ ZKLFK PDNHV LW XQOLNHO\ WKDW D GLDJQRVWLFV FRPSDQ\
would be able to bring a state law claim under the UTSA.218 That is
why this Note describes this method of maintaining competitive
advantage as a form of trade secret.
As a diagnostic laboratory conducts more tests, the lab will
invariably accrue more knowledge about the amount and type of
existing polymorphs of the gene that is the focus of the diagnostic. 219
Knowledge of the resulting disease rates correlated with certain
polymorphs will allow that lab to more accurately establish the
potential for a specific client to develop the disease associated with
abnormalities within that gene.220 As noted above, the FDA does not
currently regulate LDTs and, as such, the provider of a LDT may
currently maintain its database of knowledge concerning polymorphs
and subsequent correlation to development of disease a secret from
regulators as well.221 The idea behind maintaining this database of
knowledge as secret is that having a more powerful diagnostic, in
terms of predictive capability, that can more accurately describe a
patienW¶VSRVVLELOLW\RIGLVHDVHVKRXOGLQFUHDVHWKHFRPSHWLWLYHQHVVRI
that diagnostic in the marketplace.222 Patients and their doctors
VKRXOGZDQWWRNQRZDVPXFKDVSRVVLEOHDERXWWKHSDWLHQW¶VVSHFLILF
217.Trade Secret, BLACK¶S LAW DICTIONARY (9th ed. 2009) (emphasis added).
218.Uniform Trade Secrets $FW L  GHILQLQJWUDGHVHFUHWDV³LQIRUPDWLRQ
not being readily ascertainable by proper means by other persons who can obtain
HFRQRPLFYDOXHIURPLWVGLVFORVXUHRUXVH´ 
219.Courtenay C. Brinckerhoff, 0\ULDG¶V 7UDGH 6HFUHW 7UXPS &DUG 7KH 0\ULad
Database of Genetic Variants, FOLEY & LARDNER, LLP, available at
http://www.pharmapatentsblog.com/2013/07/18/the-myriad-database-of-geneticvariants/, archived at http://perma.cc/LS6S-X2WG.
220.Id.
221. Regulation of Genetic Tests, NATIONAL INSTITUTES OF HEALTH,
http://www.genome.gov/10002335, archived at http://perma.cc/EB7J-MWPS.
222.See Robert Cook-Deegan et al, The Next Controversy in Genetic Testing:
Clinical Data as Trade Secrets, EUROPEAN JOURNAL OF HUMAN GENETICS 21, 585588 (2013), available at
http://www.nature.com/ejhg/journal/v21/n6/full/ejhg2012217a.html.; See also
Brinckerhoff, supra note 219.
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permutation of a disease correlated gene and that patienW¶V SHUVRQDO
risk, which would allow a diagnostic laboratory with a more
powerful test to leverage their proprietary database into a sale to that
particular doctor and patient.223 However, one significant problem
with this method of maintaining competitive advantage lays in the
fact that academic research, which is generally published and made
widely available, will likely allow competitors to amass the same
knowledge concerning the disease correlation of the targeted gene.
E. Price Point Competition
Finally, price point competition is still a viable method for
maintaining competitiveness in the diagnostics marketplace. After
all, patients and insurance companies are consumers of diagnostics.
It is well established that consumers respond favorably to lower
prices.224 A diagnostics company that is able to provide a robust and
accurate test at a competitive price should be able to secure enough
market share to recoup their investment.225
CONCLUSION
Many commentators on both sides predicted the grave
consequences of the decision in Myriad. The decision in Myriad has
certainly shaken up the diagnostics market, but the promise of
genetics is too great for the industry to die. The genetic diagnostics
industry will simply need to develop a new framework by which it
attempts to protect investments into genetic research and diagnostics
development. The remaining viability of method patents should
allow many innovator companies to focus their efforts on creating
more accurate, efficient, and robust diagnostics with the security that
the methods they create to do so will likely be protected by patent.
Furthermore, federal funding into genetic research along with
increasing private academic research due to a decrease in anxiety
223.Id.
224.See Law of Demand, INVESTOPEDIA,
http://www.investopedia.com/terms/l/lawofdemand.asp, archived at
http://perma.cc/J8RW-PVVE (explaining the economic principle known as the
³/DZRI'HPDQG´ 
225.Id.
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regarding infringement suits may allow for innovator companies to
further shift their resources toward the development of diagnostics
and away from securing licenses to gene patents and researching the
link between genetic polymorphs and disease. Additionally, the
adoption of any of several proposed regulatory exclusivity schemes
would create a valuable, concrete, and secured incentive for genetic
researchers and diagnostic companies to continue using the current
exclusivity based model of protecting research and development
investment.

